President Trump’s Recognition of Pharmaceutical Cannabinoids, Especially CBD, as Medicine Signals Multi-Billion-Dollar Market Transformation — Brains Bioceutical Positioned to Lead with Pharmaceutical-Grade CBD API
News > Health News
Audio By Carbonatix
9:59 AM on Tuesday, September 30
The Associated Press
In a recent address, President Donald J. Trump described cannabinoids as “medicine,” reframing the national conversation around healthcare and aging. His remarks build on growing bipartisan momentum, with leaders such as Robert F. Kennedy Jr. also publicly supporting plant-based medicines and the companies advancing plant-based life sciences. Together, these voices signal that pharmaceutical cannabinoids are poised to move into the mainstream of U.S. medicine. In the video he posted on Truth Social on Sept. 28, 2025, the video noted that “20 percent of seniors are already using CBD today for pain, arthritis, cancer symptoms, sleep disorders, Alzheimer’s and many other ailments of aging.” Yet he also highlighted the lack of physician guidance and FDA standards, underscoring the urgent need for regulated pharmaceutical solutions.
President Trump explicitly tied cannabinoids to the body’s endocannabinoid system, discovered in the 1990s and described as a conductor that keeps all other systems in harmony. He noted that as the system weakens with age, seniors experience pain, inflammation, and cognitive decline. He described hemp-derived CBD as a “game changer” capable of restoring the system faster, reducing reliance on dangerous and addictive pharmaceuticals.
The importance of this shift cannot be overstated. In the video, President Trump cited a PricewaterhouseCoopers (PWC) analysis estimating nearly $64 billion in annual U.S. healthcare savings if cannabinoids are fully integrated into the system.
"Brains Bioceutical has already established itself as a global leader in pharmaceutical cannabinoids,” said Ricky Brar, CEO of Brains Bioceutical. “Our active pharmaceutical ingredient (API) has been utilized in more than 30 clinical studies around the world, including a co-funded NIH study, underscoring the scientific and medical community’s confidence in the quality and consistency of our molecule. We maintain a U.S. Drug Master File (DMF) that has already been referenced by one of the largest global pharmaceutical companies, further validating our regulatory strength and credibility. These achievements build on years of work to set the highest pharmaceutical standards in the cannabinoid space. To support this next phase of growth, we are engaged in discussions with leading U.S. investment banks as we evaluate potential pathways to the public markets."
Brains Bio’s Role in Meeting the Mandate
Brains Bioceutical is one of the only companies globally already manufacturing pharmaceutical-grade cannabidiol (CBD) active pharmaceutical ingredient (API). The company is positioned to serve as the backbone of this transformation by providing the regulated, standardized inputs required to develop cannabinoid-based medicines.
Brains Bio’s API is already:
- ICH-Q7 compliant, with active U.S. FDA Drug Master File (DMF), and EU ASMF filings
- Used in over 15 clinical trials, including a Phase III opioid harm reduction study jointly funded by Brains Bioceutical and the National Institutes of Health (NIH)
- Manufactured at scale, with 350+ successful commercial batches demonstrating validated consistency
- Supported by 36-month stability data to ensure global supply reliability
- NSF certified, THC-free, and tested against banned substances
- Novel Foods validated in the UK and EU, reinforcing international compliance
A Breakthrough in the U.S. Opioid Crisis
The opioid epidemic continues to devastate American communities, with economic costs estimated at over $1 trillion annually when factoring in healthcare, lost productivity, and social impacts. Solutions that can reduce dependency on addictive pharmaceuticals while offering safe, evidence-based alternatives are urgently needed.
Brains Bioceutical is addressing this crisis directly through its Phase III opioid harm reduction study, jointly funded with the NIH. This trial is designed to generate the highest level of clinical evidence on the role of pharmaceutical-grade CBD API in reducing opioid dependency and related harms.
While outcomes will depend on data, the advancement of a Phase III program with NIH involvement underscores the potential for cannabinoids to play a meaningful role in reducing opioid dependency and improving public health outcomes at scale.
Political and Market Momentum
The alignment of President Trump’s remarks with RFK Jr.’s longstanding support for plant-based medicines highlights the bipartisan potential for reform. Both leaders recognize the opportunity to reduce reliance on addictive pharmaceuticals and create economic value through innovative plant-based life sciences.
For investors, this momentum translates into one of the largest healthcare opportunities of the decade:
- Tens of millions of U.S. seniors represent the fastest-growing demographic segment
- PwC projects up to $64 billion in potential annual savings from cannabinoid integration
- The Farm Bill established the foundation; now the focus is Medicare coverage, physician education, and FDA-approved cannabinoid therapies
By describing cannabinoids as medicine, President Trump has reframed the entire conversation. APIs — not consumer-grade oils or unregulated supplements — will be the foundation of this market. With clinical validation, regulatory filings, and global-scale production, Brains Bioceutical is uniquely positioned to lead this transformation.
Brains Bioceutical (“Brains Bio” or “Brains”) is a diversified cannabinoid life sciences company with a late-stage portfolio spanning pharmaceutical assets targeting central nervous system (CNS) disorders with high unmet needs, proprietary therapies, and advanced technologies. Headquartered in Vancouver with manufacturing operations in the UK, Brains operates one of the world’s only EU-GMP certified facilities capable of producing pharmaceutical-grade cannabinoids — including cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN), and cannabigerol (CBG) — at scale. With the recent completion of its state-of-the-art Phase 2 manufacturing facility, Brains Bio is well positioned to meet growing demand as customers advance through clinical development to commercialization. The company serves pharmaceutical, nutraceutical, and veterinary partners worldwide. For more information, visit brainsbioceutical.com.Media Contact
Calvin Rasode
###
SOURCE: Brains Bioceutical
